Inclusion Criteria:  Be ≥ 18 years of age at the time the ICF is signed. Consent to submission of archival tumor tissue, if available. Adequate bone marrow, hepatic, and renal function. ECOG performance status of 0 or 1. Life expectancy of at least 6 months. Measurable disease per RECIST v1.1.  Phase 1 only:  • Patients must have an advanced/metastatic solid tumor that is refractory to or has progressed following prior treatment and has no satisfactory alternative treatment options.  Patient enrolled in Phase 2 will have one of several specific tumor types with advanced or recurrent or metastatic disease following prior therapy.  Exclusion Criteria:  Active second malignancy that may interfere with the safety or efficacy assessments of this study Symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease or with primary tumor of CNS origin. Patients must be clinically stable for at least 4 weeks without steroid treatment Received anticancer treatment ≤ 14 days prior to receiving study treatment (≤ 28 days prior in case of checkpoint inhibitor or other antibody therapies) Received prior radiopharmaceutical therapy or radioembolization, or prior extensive external beam radiation therapy (EBRT) to bone marrow or any prior EBRT to kidney, or received any EBRT within 2 weeks prior to administration of study treatment Ongoing adverse effects from anticancer treatment > Grade 1, with the exception of alopecia Known incompatibility with contrast media for CT or PET scans. Infection requiring systemic antibiotics within 2 weeks prior to administration of study treatment Impaired cardiac function or clinically significant cardiac disease Severe urinary incontinence, voiding dysfunction, or urinary obstruction Minor surgery ≤ 5 days, or major surgery ≤ 21 days, prior to administration of study treatment. Any other condition that may increase the risk associated with study participation or interfere with its interpretation. Refusal to use highly effective method of contraception, as applicable Pregnant or breastfeeding Any other condition that may increase the risk associated with study participation or interfere with its interpretation.